Comparative Pharmacology
Head-to-head clinical analysis: BENZACLIN versus MAFENIDE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZACLIN versus MAFENIDE ACETATE.
BENZACLIN vs MAFENIDE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZACLIN (clindamycin 1% and benzoyl peroxide 5%) is a combination antibacterial agent. Clindamycin is a lincosamide antibiotic that binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis and reducing Propionibacterium acnes growth. Benzoyl peroxide has bactericidal and keratolytic properties; it releases free radical oxygen species that oxidize bacterial proteins, decreasing P. acnes, and also causes drying and peeling of the skin.
Mafenide acetate is a sulfonamide antibiotic that inhibits bacterial folic acid synthesis by competitively antagonizing para-aminobenzoic acid (PABA), thereby preventing bacterial growth. It has broad-spectrum activity against gram-negative and gram-positive organisms, including Pseudomonas aeruginosa.
Topical gel applied once or twice daily to affected areas. Each gram contains 1% clindamycin and 5% benzoyl peroxide.
Apply topically as a thin layer to affected areas once or twice daily. The dosage form is an 11.1% cream or solution. The cream is applied using a sterile gloved hand; the solution is applied with a sterile spray or brush.
None Documented
None Documented
After topical application, plasma concentrations of clindamycin are negligible; the systemic half-life of clindamycin from absorbed fraction is approximately 2.5-3 hours in adults. However, due to minimal systemic absorption, the terminal half-life is not clinically relevant for topical therapy.
Approximately 45 minutes (range 30-60 minutes) for the parent compound; the metabolite p-CBS has a longer half-life of about 4 hours.
Benzaclin (clindamycin 1% - benzoyl peroxide 5%) is a topical formulation; systemic absorption is minimal. After topical application, less than 1% of clindamycin is absorbed. Absorbed clindamycin is primarily excreted in urine (10% as active drug, 90% as metabolites) and feces (<5%). Benzoyl peroxide is metabolized to benzoic acid, which is conjugated and excreted in urine. Overall, renal excretion accounts for the majority of clearance of absorbed components.
Renal: approximately 80% excreted unchanged in urine; the remainder is metabolized to p-carboxybenzene sulfonamide (p-CBS) which is also renally excreted.
Category C
Category C
Topical Antibiotic
Topical Antibiotic